Toxicity is the degree of impact of an external substance or condition and its deleterious effects on living things that include organs, tissues, cells and subcellular units. During drug discovery research, toxicity studies play an important role in identifying potential new drug candidates as it is important to assess the toxic effects of these pharmaceutical compounds for phase I clinical trials in humans. Drug discovery is centralized around pharmacokinetics mainly focusing on Absorption, Distribution, Metabolism and Excretion (ADME) profiling of the new pharmaceutical compounds. It is therefore important to combine ADME profiling with toxicology to evaluate potential drug candidates without wasting time and money on compounds that are toxic to humans. This aspect of pharmacokinetics is known as ADMET or ADME-Tox and involves taking into account the potential or real toxicity of the compound which is assessed at research facilities such as NoAb BioDiscoveries. NoAb BioDiscoveries helps to shape and optimize drug discovery research by providing a wide range of specialized and proprietary research services. These services include in vivo pharmacokinetics studies, in vitro ADME assays, Bioanalysis and Gene Expression assays.
ADMET profiling is one of the major bottlenecks in drug discovery research as information that is critical for deciding on viable drug candidates is not obtained in a rapid manner. However, NoAb BioDiscoveries is committed to accelerating the drug discovery process and saving you costs while maximizing profits. How does it do this? By constantly innovating tools and technologies that deliver faster turnaround times and focusing on lead selection and optimization which in turn ensures your success. NoAb BioDiscoveries has implemented high throughput screening (HTS) into its drug discovery process to deliver high quality and highly efficient ADMET profiling that rapidly allows the selection and prioritization of leads. In this way, ADMET is addressed as early as appropriate in the drug discovery process potentially saving the pharmaceutical developers money, making available more resources and reducing the time needed to market new drugs.
NoAb BioDiscoveries' approach to HTS ADMET profiling includes a range of in vitro assays that have been skillfully designed and are performed by highly trained and experienced scientists under strict guidelines. The assays used to provide information for ADMET profiling include cell permeability, plasma protein binding, cytochrome P450 enzyme subtype inhibition, metabolic stability in hepatocytes, metabolic stability in liver subcellular fractions, plasma stability and cytotoxicity. These assays are customized according to each customer's specifications and the scientists design the best strategies and protocols to suit any drug design. Detailed information on the HTS ADMET profiling and other in vitro and in vivo assays is available at www.noabbiodiscoveries.com. These assay protocols have been developed to provide the throughput and information necessary to assess ADMET earlier in the drug discovery process.
NoAb BioDiscoveries continuously develops advanced research tools to better characterize the ADMET properties of drug candidates, optimizing the selection of viable candidates. It is a truly dynamic research facility that has been making a remarkable impact on the path to premier drug discovery. Choose accelerated, high throughput, accurate and reliable drug discovery services from NoAb BioDiscoveries and save on costs while maximizing profits!
